{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard&page=57",
    "query": {
      "intervention": "Standard",
      "page": 57
    },
    "page_size": 10
  },
  "pagination": {
    "page": 57,
    "page_size": 10,
    "total_count": 23134,
    "total_pages": 2314,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard&page=58&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard&page=56&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T09:51:59.719Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02091960",
      "title": "A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2 Amplified",
        "Advanced Breast Cancer",
        "Human Epidermal Growth Factor Receptor 2 (HER2)"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 103,
      "start_date": "2014-09-05",
      "completion_date": "2024-01-30",
      "has_results": true,
      "last_update_posted_date": "2025-04-04",
      "last_synced_at": "2026-10-22T09:51:59.719Z",
      "location_count": 16,
      "location_summary": "Anaheim, California • Los Angeles, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02091960"
    },
    {
      "nct_id": "NCT00968838",
      "title": "A Study for Leukemia Patients With Life-Threatening Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "White Blood Cell Transfusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2009-04",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2013-11-26",
      "last_synced_at": "2026-10-22T09:51:59.719Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00968838"
    },
    {
      "nct_id": "NCT06016738",
      "title": "OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Advanced Breast Cancer",
        "Metastatic Breast Cancer",
        "ER Positive Breast Cancer",
        "HER2 Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Palazestrant",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Olema Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 510,
      "start_date": "2023-11-16",
      "completion_date": "2028-02-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-22T09:51:59.719Z",
      "location_count": 47,
      "location_summary": "Tucson, Arizona • Fountain Valley, California • Glendale, California + 39 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06016738"
    },
    {
      "nct_id": "NCT03520426",
      "title": "Evaluation of Efficacy and Safety of Votiva for Vaginal Rejuvenation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Vaginal Atrophy",
        "Vaginal Relaxation",
        "Stress Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "Votiva RF",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Walden, Jennifer L., M.D.,P.L.L.C.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "25 Years to 65 Years · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2018-03-12",
      "completion_date": "2020-01-30",
      "has_results": false,
      "last_update_posted_date": "2018-05-09",
      "last_synced_at": "2026-10-22T09:51:59.719Z",
      "location_count": 2,
      "location_summary": "New York, New York • Austin, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03520426"
    },
    {
      "nct_id": "NCT02023125",
      "title": "A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Alectinib",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "High Fat and Calorie Meal",
          "type": "OTHER"
        },
        {
          "name": "Standard Meal",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2013-12",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2016-10-07",
      "last_synced_at": "2026-10-22T09:51:59.719Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02023125"
    },
    {
      "nct_id": "NCT01549925",
      "title": "Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Standard Surgical resection",
          "type": "OTHER"
        },
        {
          "name": "LIGASURE",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2011-01",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2016-01-28",
      "last_synced_at": "2026-10-22T09:51:59.719Z",
      "location_count": 2,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01549925"
    },
    {
      "nct_id": "NCT05201976",
      "title": "Effect of a Virtually Implemented Cardiac Rehabilitation Program",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Virtually administered Cardiac Rehab program",
          "type": "OTHER"
        },
        {
          "name": "Standard of Care in person Cardiac Rehab Program",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2021-11-08",
      "completion_date": "2024-10-15",
      "has_results": false,
      "last_update_posted_date": "2024-11-06",
      "last_synced_at": "2026-10-22T09:51:59.719Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05201976"
    },
    {
      "nct_id": "NCT03442517",
      "title": "The LATCHING Pilot Project",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breastfeeding"
      ],
      "interventions": [
        {
          "name": "Behavior Lifestyle Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual prenatal care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 46,
      "start_date": "2017-04-29",
      "completion_date": "2019-05-05",
      "has_results": false,
      "last_update_posted_date": "2019-05-30",
      "last_synced_at": "2026-10-22T09:51:59.719Z",
      "location_count": 3,
      "location_summary": "Kansas City, Kansas • Kansas City, Missouri • Liberty, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Liberty",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03442517"
    },
    {
      "nct_id": "NCT02921789",
      "title": "Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplantation",
        "Primary Focal Segmental Glomerulosclerosis (FSGS)"
      ],
      "interventions": [
        {
          "name": "Bleselumab",
          "type": "DRUG"
        },
        {
          "name": "Basiliximab",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus Capsules",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2017-05-22",
      "completion_date": "2021-05-18",
      "has_results": true,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-10-22T09:51:59.719Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02921789"
    },
    {
      "nct_id": "NCT04804189",
      "title": "Reframing Firearm Injury Prevention Through Bystander Interventions for Youth",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Firearm Injury"
      ],
      "interventions": [
        {
          "name": "Guardians 4 Health",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Rhode Island Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 801,
      "start_date": "2021-09-01",
      "completion_date": "2025-08-29",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-10-22T09:51:59.719Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04804189"
    }
  ]
}